ArticleBMC cancer2025

Clinical impact of continuing osimertinib beyond progression versus best supportive care in EGFR-mutated advanced non-small cell lung cancer: a multi-institutional retrospective study.

Issei Oi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.